Medscape is available in 5 Language Editions – Choose your Edition here.


Malignant Tumors of the Sinuses Treatment & Management

  • Author: Christopher Klem, MD; Chief Editor: Arlen D Meyers, MD, MBA  more...
Updated: Mar 31, 2015

Approach Considerations

As with other types of cancers, a multimodality approach in consultation with a tumor board is recommended, including head and neck surgeon and a neurosurgeon when indicated and a neuroradiologist, pathologist, radiation oncologist, and medical oncologist as active members. Although multiple surgical and adjuvant approaches are available, a balance should be found in attempting to preserve cosmetic, oral, and nasal function. When possible, the orbit should be preserved and reconstructed. Despite these seemingly competing needs, first and foremost should be the goal of a safe and complete eradication of disease, when possible.

Although the detailed operative approaches for theses tumors are beyond the scope of this text, the authors have outlined the different options below.

A surgical review of techniques is as follows:

1 – Medial maxillectomy endoscopic

2 – Lateral rhinotomy

3 – Anterior maxillary punch

4 – Craniofacial resection

5 – Transfacial with midface degloving

6 – Infratemporal fossa approach

Treatment for recurrence includes surgery, chemotherapy, and/or radiation therapy.



Complications of treating sinus malignancies are related to the surgery and reconstruction. Surgical complications include clinically significant bleeding, CSF leak, infection, anosmia, dysgeusia, and other cranial nerve damage.[73]


Bleeding may occur if control of the large vessels is overlooked. This problem may occur if the artery is initially in vasospasm and if no active bleeding is noted until after surgery. The anterior and posterior ethmoid and sphenopalatine arteries may be cauterized, clipped, or ligated to prevent or control bleeding. If needed, interventional radiology may be requested to assist with intra-arterial coiling to control bleeding.

CSF leaks

During surgery, CSF leaks may occur near the skull base. Appropriate management starts with identification. Symptoms may include clear rhinorrhea, salty taste in the mouth, halo sign, or reservoir sign. Once noted, identification of the leak can be made endoscopically or with intrathecal injection of fluorecin. Tests, such as a test for tau or beta transferrin, may be most specific but may take days for results to be processed.

Conservative management with bed rest and a lumbar drain can be used for the first 5 days in addition to placement on antibiotics. If resolution has not occurred, surgical intervention should be used, including patching with a dermal allograft, turbinate bone, and nasal mucosa. Mucosal flaps can be elevated and used to close the leaks with interpositioned bone or cartilage. For large leaks, a spinal drain may be necessary to allow grafts and sealing techniques to solidify and integrate.


Epiphora is a common complication of surgery caused by obstruction in the lacrimal outflow tract. This can happen because of damage to the lacrimal puncta, sack, or duct. Care should be taken to marsupialize the lacrimal duct if it is lacerated or damaged in surgery to prevent outflow obstruction. Follow-up endoscopic or open dacryocystorhinostomy may be necessary.


Diplopia is a known complication in any surgery involving the orbital cone. Proper repair of the orbital floor is a key to prevent this complication, but in some cases it is unavoidable even with meticulous reconstruction. In cases of diplopia, prism lenses are usually the simplest method for correction, as surgical correction by ophthalmology can be complicated by prior scarring from surgery and radiation treatment. Ophthalmology consultation is standard of care.


One of the most difficult decisions made during surgery is when to take or leave the orbit. Suarez (2007) reviewed the literature and had 3 recommendations.[74] First, close scrutiny of the periorbita is key when deciding for or against exenteration. Although the lamina papyracea and lacrimal bones can be invaded and destroyed quite quickly, the periorbitum is a much better barrier to invasion. So despite bony destruction, if the periorbita is considered intact, they make the argument for orbital preservation and reconstruction.

Once the periorbital has been violated, orbital exenteration is required because few barriers to spread exist within the orbital contents. Second, take into account the cancer histology. When dealing with more aggressive histology such as adenocarcinoma and SCC, a lower threshold for choosing exenterations would be expected, as opposed to ENB with less local regional recurrence rates. Third, reconstruction is essential for large defects resulting from total orbital floor resection involving 2 or more orbital walls to prevent displacement and dysfunction of the eye.[74]

If the eye is preserved, postoperative radiation is usually recommended. Current treatments are precise in XRT delivery and preserving orbital function. Nonetheless, patients should be counseled that despite surgical orbital preservation, impairment can occur from XRT, including optic atrophy, cataracts, dry eye, and ectropion.[75]

In the ideal cases, reconstruction preserves form and function. A free rectus flap or other distant tissue may be required to protect vital structures, or facial prosthetics may be used. Facial prosthesis can be offered to improve cosmetic results, but meticulous maintenance of the prosthesis by the team and patient is imperative.

Facial disfiguration is one of the most important patient concerns and can lead to considerable social and psychological stress. This outcome must be dealt with initially and on an ongoing basis.

Flap reconstruction, instead of wearing a prosthesis during recovery, is an option for patients undergoing reconstruction for maxillectomy defects; however, it is associated with a longer recovery time, higher procedure costs, and increased risk of surgical complications. Additionally, the patient must be under the care of a highly experienced surgeon. The surgeon and reconstructive team should make individualized decisions after considering the extent of the maxillectomy defect and the need for radiation therapy.[76]


Outcome and Prognosis

Survival rates for patients with maxillary sinus cancer average about 40% over 5 years. Early-stage tumors have a cure rate of up to 80%. Patients with unresectable tumors treated with radiation have a survival rate of less than 20%. Survival rates for ethmoid tumors have improved slightly because of advances in skull-base surgery.


Future and Controversies

Although intra-arterial chemotherapy was used in the past, it was only recently shown to be consistently effective. With the advent of thiosulfate, a neutralizer of cisplatin, physicians can now deliver large doses of intra-arterial chemotherapy more safely than before. High-dose cisplatin is administered by means of the arterial blood supply of the tumor. A simultaneous infusion of thiosulfate prevents the systemic effects of cisplatin.

Intra-arterial chemotherapy is used with radiation and had promising results in preserving organs and in managing bulky nodal disease.

Given the anatomy of the paranasal sinuses and their blood supply, intra-arterial chemotherapy may be an effective method of treating sinus malignancies.

Contributor Information and Disclosures

Christopher Klem, MD Attending Surgeon, Chief, Head and Neck Oncologic Surgery, Microvascular Reconstructive Surgery, Assistant Chief, Otolaryngology–Head and Neck Surgery Service, Tripler Army Medical Center

Christopher Klem, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society, American Medical Association, American Society for Reconstructive Microsurgery

Disclosure: Nothing to disclose.


Jared M Theler, MD Resident Physician in Otolaryngology-Head and Neck Surgery, Department of Surgery, Tripler Army Medical Center

Jared M Theler, MD is a member of the following medical societies: American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American Medical Association, Association of Military Surgeons of the US

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Karen H Calhoun, MD, FACS, FAAOA Professor, Department of Otolaryngology-Head and Neck Surgery, Ohio State University College of Medicine

Karen H Calhoun, MD, FACS, FAAOA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Head and Neck Society, Association for Research in Otolaryngology, Southern Medical Association, American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Medical Association, American Rhinologic Society, Society of University Otolaryngologists-Head and Neck Surgeons, Texas Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Arlen D Meyers, MD, MBA Professor of Otolaryngology, Dentistry, and Engineering, University of Colorado School of Medicine

Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cerescan;RxRevu;SymbiaAllergySolutions<br/>Received income in an amount equal to or greater than $250 from: Symbia<br/>Received from Allergy Solutions, Inc for board membership; Received honoraria from RxRevu for chief medical editor; Received salary from Medvoy for founder and president; Received consulting fee from Corvectra for senior medical advisor; Received ownership interest from Cerescan for consulting; Received consulting fee from Essiahealth for advisor; Received consulting fee from Carespan for advisor; Received consulting fee from Covidien for consulting.

Additional Contributors

William M Lydiatt, MD Professor and Division Director, Head and Neck Surgical Oncology, Department of Otolaryngology-Head and Neck Surgery, University of Nebraska Medical Center

William M Lydiatt, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society, Nebraska Medical Association

Disclosure: Nothing to disclose.

  1. Robin PE, Powell DJ, Stansbie JM. Carcinoma of the nasal cavity and paranasal sinuses: incidence and presentation of different histological types. Clin Otolaryngol Allied Sci. 1979 Dec. 4(6):431-56. [Medline].

  2. Bridger GP, Mendelsohn MS, Baldwin M, Smee R. Paranasal sinus cancer. Aust N Z J Surg. 1991 Apr. 61(4):290-4. [Medline].

  3. Golabek W, Drop A, Golabek E, Morshed K. Site of origin of paranasal sinus malignancies [in Polish]. Pol Merkuriusz Lek. 2005 Sep. 19(111):413-4. [Medline].

  4. Larsson LG, Martensson G. Carcinoma of the paranasal sinuses and the nasal cavities; a clinical study of 379 cases treated at Radiumhemmet and the Otolaryngologic Department of Karolinska Sjukhuset, 1940-1950. Acta radiol. 1954 Aug. 42(2):149-72. [Medline].

  5. Bornholdt J, Hansen J, Steiniche T, et al. K-ras mutations in sinonasal cancers in relation to wood dust exposure. BMC Cancer. 2008 Feb 20. 8:53. [Medline].

  6. Klintenberg C, Olofsson J, Hellquist H, Sokjer H. Adenocarcinoma of the ethmoid sinuses. A review of 28 cases with special reference to wood dust exposure. Cancer. 1984 Aug 1. 54(3):482-8. [Medline].

  7. Luce D, Gerin M, Leclerc A, Morcet JF, Brugere J, Goldberg M. Sinonasal cancer and occupational exposure to formaldehyde and other substances. Int J Cancer. 1993 Jan 21. 53(2):224-31. [Medline].

  8. Katori H, Nozawa A, Tsukuda M. Markers of malignant transformation of sinonasal inverted papilloma. Eur J Surg Oncol. 2005 Oct. 31(8):905-11. [Medline].

  9. McKay SP, Gregoire L, Lonardo F, Reidy P, Mathog RH, Lancaster WD. Human papillomavirus (HPV) transcripts in malignant inverted papilloma are from integrated HPV DNA. Laryngoscope. 2005 Aug. 115(8):1428-31. [Medline].

  10. Ott G, Kalla J, Ott MM, Muller-Hermelink HK. The Epstein-Barr virus in malignant non-Hodgkin's lymphoma of the upper aerodigestive tract. Diagn Mol Pathol. 1997 Jun. 6(3):134-9. [Medline].

  11. Katori H, Nozawa A, Tsukuda M. Histopathological parameters of recurrence and malignant transformation in sinonasal inverted papilloma. Acta Otolaryngol. 2006 Feb. 126(2):214-8. [Medline].

  12. Fooanant S, Pattarasakulchai T, Tananuvat R, Sittitrai P, Chaiyasate S, Roongrotwattanasiri K, et al. Sinonasal papilloma in Chiang Mai University Hospital. J Med Assoc Thai. 2013 Mar. 96(3):329-33. [Medline].

  13. Waitz G, Wigand ME. Results of endoscopic sinus surgery for the treatment of inverted papillomas. Laryngoscope. 1992 Aug. 102(8):917-22. [Medline].

  14. Krouse JH. Endoscopic treatment of inverted papilloma: safety and efficacy. Am J Otolaryngol. 2001 Mar-Apr. 22(2):87-99. [Medline].

  15. Busquets JM, Hwang PH. Endoscopic resection of sinonasal inverted papilloma: a meta-analysis. Otolaryngol Head Neck Surg. 2006 Mar. 134(3):476-82. [Medline].

  16. Poetker DM, Toohill RJ, Loehrl TA, Smith TL. Endoscopic management of sinonasal tumors: a preliminary report. Am J Rhinol. 2005 May-Jun. 19(3):307-15. [Medline].

  17. Oikawa K, Furuta Y, Nakamaru Y, Oridate N, Fukuda S. Preoperative staging and surgical approaches for sinonasal inverted papilloma. Ann Otol Rhinol Laryngol. 2007 Sep. 116(9):674-80. [Medline].

  18. Cannady SB, Batra PS, Sautter NB, Roh HJ, Citardi MJ. New staging system for sinonasal inverted papilloma in the endoscopic era. Laryngoscope. 2007 Jul. 117(7):1283-7. [Medline].

  19. Suh JD, Ramakrishnan VR, Thompson CF, et al. Inverted papilloma of the sphenoid sinus: Risk factors for disease recurrence. Laryngoscope. 2015 Mar. 125(3):544-8. [Medline].

  20. Tiwari R, Hardillo JA, Mehta D, et al. Squamous cell carcinoma of maxillary sinus. Head Neck. 2000 Mar. 22(2):164-9. [Medline].

  21. Batsakis JG, Rice DH, Solomon AR. The pathology of head and neck tumors: squamous and mucous-gland carcinomas of the nasal cavity, paranasal sinuses, and larynx, part 6. Head Neck Surg. 1980 Jul-Aug. 2(6):497-508. [Medline].

  22. Lavertu P, Roberts JK, Kraus DH, Levine HL, Wood BG, Medendorp SV. Squamous cell carcinoma of the paranasal sinuses: the Cleveland Clinic experience 1977-1986. Laryngoscope. 1989 Nov. 99(11):1130-6. [Medline].

  23. Lee CH, Hur DG, Roh HJ, et al. Survival rates of sinonasal squamous cell carcinoma with the new AJCC staging system. Arch Otolaryngol Head Neck Surg. 2007 Feb. 133(2):131-4. [Medline].

  24. Shipchandler TZ, Batra PS, Citardi MJ, Bolger WE, Lanza DC. Outcomes for endoscopic resection of sinonasal squamous cell carcinoma. Laryngoscope. 2005 Nov. 115(11):1983-7. [Medline].

  25. Weiss MD, deFries HO, Taxy JB, Braine H. Primary small cell carcinoma of the paranasal sinuses. Arch Otolaryngol. 1983 May. 109(5):341-3. [Medline].

  26. Huber PE, Debus J, Latz D, Zierhut D, Bischof M, Wannenmacher M. Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam?. Radiother Oncol. 2001 May. 59(2):161-7. [Medline].

  27. Douglas JG, Laramore GE, Austin-Seymour M, Koh WJ, Lindsley KL, Cho P. Neutron radiotherapy for adenoid cystic carcinoma of minor salivary glands. Int J Radiat Oncol Biol Phys. 1996 Aug 1. 36(1):87-93. [Medline].

  28. Laramore GE, Krall JM, Griffin TW, et al. Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys. 1993 Sep 30. 27(2):235-40. [Medline].

  29. Lupinetti AD, Roberts DB, Williams MD, et al. Sinonasal adenoid cystic carcinoma: the M. D. Anderson Cancer Center experience. Cancer. 2007 Dec 15. 110(12):2726-31. [Medline].

  30. Van Gerven L, Jorissen M, Nuyts S, Hermans R, Vander Poorten V. Long-term follow-up of 44 patients with adenocarcinoma of the nasal cavity and sinuses primarily treated with endoscopic resection followed by radiotherapy. Head Neck. 2011 Jun. 33(6):898-904. [Medline].

  31. Alessi DM, Trapp TK, Fu YS, Calcaterra TC. Nonsalivary sinonasal adenocarcinoma. Arch Otolaryngol Head Neck Surg. 1988 Sep. 114(9):996-9. [Medline].

  32. Heffner DK, Hyams VJ, Hauck KW, Lingeman C. Low-grade adenocarcinoma of the nasal cavity and paranasal sinuses. Cancer. 1982 Jul 15. 50(2):312-22. [Medline].

  33. Moran CA, Wenig BM, Mullick FG. Primary adenocarcinoma of the nasal cavity and paranasal sinuses. Ear Nose Throat J. 1991 Dec. 70(12):821-8. [Medline].

  34. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998 Oct 15. 83(8):1664-78. [Medline].

  35. Medina JE, Ferlito A, Pellitteri PK, Shaha AR, Khafif A, Devaney KO. Current management of mucosal melanoma of the head and neck. J Surg Oncol. 2003 Jun. 83(2):116-22. [Medline].

  36. Manolidis S, Donald P. Malignant Mucousal Melanoma of the Head and Neck. Head and Neck. 1997. 80(8):1373-1386. [Medline].

  37. Dauer EH, Lewis JE, Rohlinger AL, Weaver AL, Olsen KD. Sinonasal melanoma: a clinicopathologic review of 61 cases. Otolaryngol Head Neck Surg. 2008 Mar. 138(3):347-52. [Medline].

  38. Billings KR, Wang MB, Sercarz JA, Fu YS. Clinical and pathologic distinction between primary and metastatic mucosal melanoma of the head and neck. Otolaryngol Head Neck Surg. 1995 Jun. 112(6):700-6. [Medline].

  39. Rosenthal DI, Barker JL Jr, El-Naggar AK, et al. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer. 2004 Dec 1. 101(11):2567-73. [Medline].

  40. Hyams VJ. Tumors of the upper respiratory tract and ear. Atlas of Tumor Pathology. 2nd series. Fascicle 25. Washington D.C: Armed Forces Institute of Pathology; 1988. 240-248.

  41. Kameya T, Shimosato Y, Adachi I, Abe K, Ebihara S, Ono I. Neuroendocrine carcinoma of the paranasal sinus: a morphological and endocrinological study. Cancer. 1980 Jan 15. 45(2):330-9. [Medline].

  42. Sirsath NT, Babu KG, Das U, Premlatha CS. Paranasal sinus neuroendocrine carcinoma: a case report and review of the literature. Case Rep Oncol Med. 2013. 2013:728479. [Medline]. [Full Text].

  43. Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res. 1997 Jul-Aug. 17(4A):2683-706. [Medline].

  44. Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2001 Nov. 2(11):683-90. [Medline].

  45. McElroy EA Jr, Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery. 1998 May. 42(5):1023-7; discussion 1027-8. [Medline].

  46. Diaz EM Jr, Johnigan RH 3rd, Pero C, et al. Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck. 2005 Feb. 27(2):138-49. [Medline].

  47. Loy AH, Reibel JF, Read PW, et al. Esthesioneuroblastoma: continued follow-up of a single institution's experience. Arch Otolaryngol Head Neck Surg. 2006 Feb. 132(2):134-8. [Medline].

  48. Levine PA, Gallagher R, Cantrell RW. Esthesioneuroblastoma: reflections of a 21-year experience. Laryngoscope. 1999 Oct. 109(10):1539-43. [Medline].

  49. Rischin D, Porceddu S, Peters L, Martin J, Corry J, Weih L. Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma. Head Neck. 2004 May. 26(5):435-41. [Medline].

  50. Chen A, Daly M, El-Sayed I, et al. Patterns of Failure After Combined-Modality Approaches Incorporating Radiotherapy for Sinonasal Undifferentiated Carcinoma of the Head and Neck. Oncology Bio Phys Inter J. Radiation. 2007. 70(2):338-343.

  51. Frierson HF Jr, Mills SE, Fechner RE, Taxy JB, Levine PA. Sinonasal undifferentiated carcinoma. An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma. Am J Surg Pathol. 1986 Nov. 10(11):771-9. [Medline].

  52. Gallo O, Graziani P, Fini-Storchi O. Undifferentiated carcinoma of the nose and paranasal sinuses. An immunohistochemical and clinical study. Ear Nose Throat J. 1993 Sep. 72(9):588-90, 593-5. [Medline].

  53. Uchida D, Shirato H, Onimaru R, et al. Long-term results of ethmoid squamous cell or undifferentiated carcinoma treated with radiotherapy with or without surgery. Cancer J. 2005 Mar-Apr. 11(2):152-6. [Medline].

  54. Medina JE, Dichtel W, Luna MA. Verrucous-squamous carcinomas of the oral cavity. A clinicopathologic study of 104 cases. Arch Otolaryngol. 1984 Jul. 110(7):437-40. [Medline].

  55. Kapadia SB, Barnes L, Deutsch M. Non-Hodgkin's lymphoma of the nose and paranasal sinuses: a study of 17 cases. Head Neck Surg. 1981 Jul-Aug. 3(6):490-9. [Medline].

  56. Abbondanzo SL, Wenig BM. Non-Hodgkin's lymphoma of the sinonasal tract. A clinicopathologic and immunophenotypic study of 120 cases. Cancer. 1995 Mar 15. 75(6):1281-91. [Medline].

  57. Petrella T, Delfau-Larue MH, Caillot D, et al. Nasopharyngeal lymphomas: further evidence for a natural killer cell origin. Hum Pathol. 1996 Aug. 27(8):827-33. [Medline].

  58. Dubal PM, Dutta R, Vazquez A, et al. A comparative population-based analysis of sinonasal diffuse large B-cell and extranodal NK/T-cell lymphomas. Laryngoscope. 2014 Dec 27. [Medline].

  59. Kimura Y, Tanaka S, Furukawa M. Angiosarcoma of the nasal cavity. J Laryngol Otol. 1992 Apr. 106(4):368-9. [Medline].

  60. Nappi O, Wick MR. Sarcomatoid neoplasms of the respiratory tract. Semin Diagn Pathol. 1993 May. 10(2):137-47. [Medline].

  61. Aust MR, Olsen KD, Lewis JE, et al. Angiosarcomas of the head and neck: clinical and pathologic characteristics. Ann Otol Rhinol Laryngol. 1997 Nov. 106(11):943-51. [Medline].

  62. Zevallos JP, Jain KS, Roberts D, El-Naggar A, Hanna EY, Kupferman ME. Sinonasal malignancies in children: A 10-year, single-institutional review. Laryngoscope. 2011 Jul 7. [Medline].

  63. Yamasoba T, Kikuchi S, Sugasawa M, Higo R, Sasaki T. Occult follicular carcinoma metastasizing to the sinonasal tract. ORL J Otorhinolaryngol Relat Spec. 1994 Jul-Aug. 56(4):239-43. [Medline].

  64. Frigy AF. Metastatic hepatocellular carcinoma of the nasal cavity. Arch Otolaryngol. 1984 Sep. 110(9):624-7. [Medline].

  65. Cantù G, Bimbi G, Miceli R, et al. Lymph node metastases in malignant tumors of the paranasal sinuses: prognostic value and treatment. Arch Otolaryngol Head Neck Surg. 2008 Feb. 134(2):170-7. [Medline].

  66. Raghavan P, Phillips CD. Magnetic resonance imaging of sinonasal malignancies. Top Magn Reson Imaging. 2007 Aug. 18(4):259-67. [Medline].

  67. Yousem DM, Gad K, Tufano RP. Resectability issues with head and neck cancer. AJNR Am J Neuroradiol. 2006 Nov-Dec. 27(10):2024-36. [Medline].

  68. Schuster JJ, Phillips CD, Levine PA. MRI of olfactory neuroblastoma and appearance after craniofacial resection. AJNR Am J Neuroradiology. 1994. 15:1169-1177.

  69. Sasaki M, Eida S, Sumi M, Nakamura T. Apparent diffusion coefficient mapping for sinonasal diseases: differentiation of benign and malignant lesions. AJNR Am J Neuroradiol. 2011 Jun. 32(6):1100-6. [Medline].

  70. Shojaku H, Fujisaka M, Yasumura S, et al. Positron emission tomography for predicting malignancy of sinonasal inverted papilloma. Clin Nucl Med. 2007 Apr. 32(4):275-8. [Medline].

  71. Nasal cavity and paranasal sinuses. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. Springer; 2002. 59-67.

  72. Shojaku H, Fujisaka M, Yasumura S, Ishida M, Tsubota M, Nishida H. Positron emission tomography for predicting malignancy of sinonasal inverted papilloma. Clin Nucl Med. 2007 Apr. 32(4):275-8. [Medline].

  73. Suh JD, Ramakrishnan VR, Chi JJ, Palmer JN, Chiu AG. Outcomes and complications of endoscopic approaches for malignancies of the paranasal sinuses and anterior skull base. Ann Otol Rhinol Laryngol. 2013 Jan. 122(1):54-9. [Medline].

  74. Suarez C. Management of the Orbit in Maligant Sinonasal Tumors. Head and Neck. Head and Neck. 242-250.

  75. Medina JE, Ferlito A, Pellitteri PK, et al. Current management of mucosal melanoma of the head and neck. J Surg Oncol. 2003 Jun. 83(2):116-22. [Medline].

  76. Andrades P, Militsakh O, Hanasono MM, Rieger J, Rosenthal EL. Current strategies in reconstruction of maxillectomy defects. Arch Otolaryngol Head Neck Surg. 2011 Aug. 137(8):806-12. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.